Home Forums Obstetrics & Gynaecology A Vaccine for Ovarian Cancer

Viewing 0 reply threads
  • Author
    Posts
    • #4934

      The world’s first vaccine for ovarian cancer – being developed in the UK – could wipe out the deadly disease, researchers say. Scientists at the University of Oxford are creating OvarianVax, a vaccine that teaches the immune system to recognise and attack the earliest stages of ovarian cancer.

      Experts suggest it could work in a similar way to the human papillomavirus (HPV) jab, which is on track to stamp out cervical cancer. For the new work, Professor Ahmed Ahmed, director of the ovarian cancer cell laboratory at MRC Weatherall Institute of Molecular Medicine the University of Oxford, and his team are identifying cellular targets for the vaccine.

      They will establish which proteins on the surface of early-stage ovarian cancer cells are most strongly recognised by the immune system, and how effectively the vaccine kills mini-models of ovarian cancer in the lab. They will then move on to human clinical trials in people with BRCA gene mutations – which massively increase the risk of ovarian cancer – and healthy women in the general population to see if the disease could be prevented.

      Cancer Research UK is funding the study with up to £600,000 over the next three years. Prof Ahmed said that, if the jab is successful, he would expect to start seeing an impact within the next five years.

      For the work, scientists will create the vaccine in the lab, with the aim of training the immune system to recognise more than 100 proteins on the surface of ovarian cancer, known as tumour-associated antigens. They will then move to testing the vaccine in patients with the disease.

      Prof Ahmed said: “The idea is, if you give the vaccine, these tiny tumours will hopefully either reduce, shrink really significantly, or disappear. That would give us the sign that the vaccine is working.”

      The next stage would then be to include women with BRCA mutations and a wider general population of women without known disease to see whether “the vaccine would be suitable for all” in preventing ovarian cancer.

      The obvious population who would benefit from this are the BRCA1 and BRCA2 mutation carriers, because they have a very high chance of getting ovarian cancer. At the moment, there is no screening test for ovarian cancer, which is often diagnosed in late stages because the symptoms – such as bloating and no appetite – can be vague.

      it is known that women with BRCA mutations are at high risk. Almost 45 per cent of people with an altered BRCA1 gene and almost 20% with an altered BRCA2 gene will develop ovarian cancer by the age of 80, compared with just two per cent in the general population.

      Currently, women with BRCA1/2 alterations are recommended to have their ovaries removed by the age of 35, which means they go through early menopause. Prof Ahmed said BRCA mutation carriers could benefit greatly from the new vaccine because “they wouldn’t then have to have their ovaries removed”.

      He said that, through the clinical trials, he would hope to start seeing the impact of the vaccine “in four or five years on the healthy population”. There are around 7,500 new ovarian cancer cases every year in the UK, with BRCA mutations accounting for around 5-15 per cent of these cases.

      The article is extracted from a report by Jane Kirby of The Scotsman

Viewing 0 reply threads
  • You must be logged in to reply to this topic.